Preclinical studies revealed that Venetoclax demonstrated specific ability of killing MYC+/BCL2 + lymphoma cells by enhancing antigen-specific effector T-cell responses and antagonizing BCL-2.34 Venetoclax also exhibits synergistic anti-tumor effects when combined with rituximab and HDACi in DEL mice.35,36 These noticeable results have attracted clinicians to explore the applicability of BCL-2 inhibitors in the treatment of DEL. Here, MYC is linked to lymphoma.